FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221047810> ?p ?o ?g. }

• W4221047810 abstract "Abstract Objectives To evaluate the safety and immunogenicity of third and fourth BNT162b2 boosters in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients. Methods SLE and RA patients aged 18-65 years who completed a series of inactivated, adenoviral vector, or heterogenous adenoviral vector/mRNA vaccines for at least 28 days were enrolled. Immunogenicity assessment was done before and day 15 after each booster vaccination. The third BNT162b2 booster was administered on day 1. Patients with suboptimal humoral response to the third booster dose (anti-receptor binding domain (RBD) IgG on day 15 < 2,360 BAU/mL) were given a fourth BNT162b2 booster on day 22. Results Seventy one SLE and 29 RA patients were enrolled. The third booster raised anti-RBD IgG by 15 fold and patients with positive neutralizing activity against the Omicron variant increased from 0% to 42%. Patients with positive cellular immune response also increased from 55% to 94%. High immunosuppressive load and initial inactivated vaccine were associated with lower anti-RBD IgG titer. Fifty four patients had suboptimal humoral responses to the third booster and 28 received a fourth booster dose. Although anti-RBD IgG increased further by 7 fold, no significant change in neutralizing activity against the Omicron variant was observed. There were 2 severe SLE flares that occurred shortly after the fourth booster dose. Conclusions The third BNT162b2 booster significantly improved humoral and cellular immunogenicity in SLE and RA patients. The benefit of a short interval fourth booster in patients with suboptimal humoral response was unclear. Key messages What is already known about this subject? - The SARS-CoV-2 omicron variant (B.1.1.159) has multiple mutations that have resulted in greater escape from immune protection elicited by COVID-19 vaccines. - More attenuated immune response to SARS-CoV-2 vaccination has been observed in patients with autoimmune rheumatic diseases. The additional third dose of SARS-CoV-2 vaccine has been recommended in immunocompromised populations. - Some immunocompromised patients have a suboptimal humoral response to a third booster dose. Factors associated with poor immune response have not been adequately studied. - Administration of more than 3 doses has been shown to enhance immune response in some severely immunocompromised patients. What does this study add? - The third BNT162b2 booster was well tolerated, and significantly improved both humoral and cellular immunogenicity in SLE and RA patients previously vaccinated with either inactivated, adenoviral vector, or heterogenous adenoviral vector/mRNA vaccines. - High intensity of immunosuppressive therapy and initial inactivated vaccine were associated with lower humoral immune response to the third BNT162b2 booster. - Administration of a fourth BNT162b2 booster in poor humoral immune responders may not offer additional protection against the omicron variant, and flares were observed in SLE patients. How might this impact on clinical practice or future developments? - This study supported a third BNT162b2 booster dose administration in SLE and RA patients to enhance immune protection against the Omicron variant. - Patients who receive a high dose of immunosuppressive therapy or initial inactivated vaccine could be unprotected from SARS-CoV-2 infection. Benefits and risks of additional boosters or second generation of SARS-CoV-2 vaccine should be further studied." @default.
• W4221047810 created "2022-04-03" @default.
• W4221047810 creator A5009806977 @default.
• W4221047810 creator A5011661934 @default.
• W4221047810 creator A5013392320 @default.
• W4221047810 creator A5067543646 @default.
• W4221047810 creator A5070358085 @default.
• W4221047810 creator A5072932253 @default.
• W4221047810 creator A5079500426 @default.
• W4221047810 creator A5084305363 @default.
• W4221047810 date "2022-03-15" @default.
• W4221047810 modified "2023-09-27" @default.
• W4221047810 title "Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in systemic lupus erythematosus and rheumatoid arthritis patients" @default.
• W4221047810 cites W2062036448 @default.
• W4221047810 cites W2116335283 @default.
• W4221047810 cites W3139524064 @default.
• W4221047810 cites W3165239056 @default.
• W4221047810 cites W3174017401 @default.
• W4221047810 cites W3176668337 @default.
• W4221047810 cites W3177819637 @default.
• W4221047810 cites W3190427561 @default.
• W4221047810 cites W3214308382 @default.
• W4221047810 cites W4206040938 @default.
• W4221047810 cites W4206675538 @default.
• W4221047810 cites W4207076468 @default.
• W4221047810 cites W4210493562 @default.
• W4221047810 cites W4210674949 @default.
• W4221047810 cites W4210792795 @default.
• W4221047810 cites W4210844692 @default.
• W4221047810 cites W4225505308 @default.
• W4221047810 cites W4225854071 @default.
• W4221047810 cites W4226229183 @default.
• W4221047810 doi "https://doi.org/10.1101/2022.03.15.22272350" @default.
• W4221047810 hasPublicationYear "2022" @default.
• W4221047810 type Work @default.
• W4221047810 citedByCount "2" @default.
• W4221047810 countsByYear W42210478102022 @default.
• W4221047810 countsByYear W42210478102023 @default.
• W4221047810 crossrefType "posted-content" @default.
• W4221047810 hasAuthorship W4221047810A5009806977 @default.
• W4221047810 hasAuthorship W4221047810A5011661934 @default.
• W4221047810 hasAuthorship W4221047810A5013392320 @default.
• W4221047810 hasAuthorship W4221047810A5067543646 @default.
• W4221047810 hasAuthorship W4221047810A5070358085 @default.
• W4221047810 hasAuthorship W4221047810A5072932253 @default.
• W4221047810 hasAuthorship W4221047810A5079500426 @default.
• W4221047810 hasAuthorship W4221047810A5084305363 @default.
• W4221047810 hasBestOaLocation W42210478101 @default.
• W4221047810 hasConcept C121332964 @default.
• W4221047810 hasConcept C12590561 @default.
• W4221047810 hasConcept C1276947 @default.
• W4221047810 hasConcept C159654299 @default.
• W4221047810 hasConcept C203014093 @default.
• W4221047810 hasConcept C203165030 @default.
• W4221047810 hasConcept C2777575956 @default.
• W4221047810 hasConcept C2780868878 @default.
• W4221047810 hasConcept C32611913 @default.
• W4221047810 hasConcept C71924100 @default.
• W4221047810 hasConcept C8891405 @default.
• W4221047810 hasConceptScore W4221047810C121332964 @default.
• W4221047810 hasConceptScore W4221047810C12590561 @default.
• W4221047810 hasConceptScore W4221047810C1276947 @default.
• W4221047810 hasConceptScore W4221047810C159654299 @default.
• W4221047810 hasConceptScore W4221047810C203014093 @default.
• W4221047810 hasConceptScore W4221047810C203165030 @default.
• W4221047810 hasConceptScore W4221047810C2777575956 @default.
• W4221047810 hasConceptScore W4221047810C2780868878 @default.
• W4221047810 hasConceptScore W4221047810C32611913 @default.
• W4221047810 hasConceptScore W4221047810C71924100 @default.
• W4221047810 hasConceptScore W4221047810C8891405 @default.
• W4221047810 hasLocation W42210478101 @default.
• W4221047810 hasOpenAccess W4221047810 @default.
• W4221047810 hasPrimaryLocation W42210478101 @default.
• W4221047810 hasRelatedWork W2034020186 @default.
• W4221047810 hasRelatedWork W2411114470 @default.
• W4221047810 hasRelatedWork W4200165852 @default.
• W4221047810 hasRelatedWork W4210690844 @default.
• W4221047810 hasRelatedWork W4220654690 @default.
• W4221047810 hasRelatedWork W4221113218 @default.
• W4221047810 hasRelatedWork W4293746688 @default.
• W4221047810 hasRelatedWork W4304784005 @default.
• W4221047810 hasRelatedWork W4321231441 @default.
• W4221047810 hasRelatedWork W618659585 @default.
• W4221047810 isParatext "false" @default.
• W4221047810 isRetracted "false" @default.
• W4221047810 workType "article" @default.